Back to top
more

Editas Medicine (EDIT)

(Delayed Data from NSDQ)

$2.66 USD

2.66
2,503,145

-0.11 (-3.97%)

Updated Nov 15, 2024 04:00 PM ET

After-Market: $2.66 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value F Growth A Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 29% (72 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks News

Editas Q3 Loss Narrower Than Expected, Revenues Decrease Y/Y

EDIT reports mixed third-quarter 2024 results as earnings beat expectations while revenues miss the same.

How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings

Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.

Editas Medicine (EDIT) Reports Q3 Loss, Misses Revenue Estimates

Editas (EDIT) delivered earnings and revenue surprises of 1.32% and 99.13%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate Adherex Technologies Inc. (FENC) to Report a Decline in Earnings: What to Look Out for

Adherex Technologies (FENC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Editas Medicine (EDIT) Q3 Earnings Expected to Decline

Editas (EDIT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Biotech Stock Roundup: FOLD Settles Patent Dispute, Updates From EDIT & More

FOLD and EDIT are in the spotlight following patent dispute settlement news and strategic updates, respectively.

EDIT Seeks Partner for Reni-Cel Developmental Program, Stock Down

Editas stock falls on a decision to seek a partner for its lead gene-therapy candidate, reni-cell, for SCD and TDT and focus resources on in vivo pipeline development.

EDIT Inks Collaboration Deal to Develop Novel Gene Editing Therapies

Editas signs a license agreement with Genevant Sciences to develop novel mRNA-LNP gene editing therapeutics. Shares rise in after-hours trading.

Editas (EDIT) Down 17% Since Last Earnings Report: Can It Rebound?

Editas (EDIT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Sundeep Ganoria  headshot

CRISPR (CRSP) Loses 24% YTD: How Should You Play the Stock?

Despite gaining regulatory approvals in many countries for the first ever CRISPR-based gene therapy, investors should remain wary of investing in CRISPR Therapeutics' (CRSP) early-stage pipeline.

Editas (EDIT) Q2 Earnings & Revenues Miss Estimates, Stock Down

Editas (EDIT) reports lower-than-expected second-quarter 2024 results as both earnings and revenues miss estimates. The stock falls 12.2%.

Editas Medicine (EDIT) Reports Q2 Loss, Misses Revenue Estimates

Editas (EDIT) delivered earnings and revenue surprises of -18.84% and 92.44%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Illumina (ILMN) Q2 Earnings and Revenues Top Estimates

Illumina (ILMN) delivered earnings and revenue surprises of 200% and 1.31%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Lexicon Pharmaceuticals (LXRX) Reports Q2 Loss, Misses Revenue Estimates

Lexicon (LXRX) delivered earnings and revenue surprises of 5.56% and 39.80%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Editas (EDIT) Reports Upbeat New Data From Reni-Cel Studies

Editas (EDIT) reports positive new safety and efficacy data from the RUBY and EdiTHAL studies evaluating its investigational gene therapy, reni-cel, for SCD and TDT, respectively.

Editas (EDIT) Down 2.3% Since Last Earnings Report: Can It Rebound?

Editas (EDIT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Editas (EDIT) Q1 Earnings & Revenues Lag Estimates, Stock Down

Editas (EDIT) reports weaker-than-expected first-quarter 2024 results as both earnings and revenues fall shy of estimates. Shares fall.

Editas Medicine (EDIT) Reports Q1 Loss, Misses Revenue Estimates

Editas (EDIT) delivered earnings and revenue surprises of -20.63% and 90.26%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

The Zacks Analyst Blog Highlights Gilead Sciences, GSK, Deciphera, Bristol Myers and Editas Medicine

Gilead Sciences, GSK, Deciphera, Bristol Myers and Editas Medicine are included in this Analyst Blog.

Biotech Stock Roundup: GILD's GSK' Q1 Earnings, DCPH Soars on Acquisition News & More

Deciphera Pharmaceuticals, Inc. (DCPH) and GSK are in focus on acquisition news and Q1 earnings, respectively.

Will Editas Medicine (EDIT) Report Negative Q1 Earnings? What You Should Know

Editas (EDIT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Why Is Editas (EDIT) Down 26.2% Since Last Earnings Report?

Editas (EDIT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Editas (EDIT) Q4 Earnings & Revenues Top Estimates, Stock Up

Editas (EDIT) reports better-than-expected fourth-quarter 2023 results as both earnings and revenues beat estimates, driven by collaboration revenues received from Vertex. The stock gains 25%.

Editas Medicine (EDIT) Reports Q4 Loss, Tops Revenue Estimates

Editas (EDIT) delivered earnings and revenue surprises of 55.77% and 347.63%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Krystal Biotech, Inc. (KRYS) Tops Q4 Earnings and Revenue Estimates

Krystal Biotech, Inc. (KRYS) delivered earnings and revenue surprises of 157.69% and 119.92%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?